 LA JOLLA, Calif., Aug. 3, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates AOCsTM, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of 18.00 per share. 